Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA2 | Q15349 | 8/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 2/20 | 0.34 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | PTPRC | P08575 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL50159 | 0.87 | L3MBTL1 (0.36) | HSD17B10KMT2A | |
| SCHEMBL50693 | 0.83 | RPS6KA3 (0.46) | RPS6KA2RPS6KA3FGFR1 | |
| SCHEMBL3574670 | 0.73 | SRD5A2 (0.50) | RPS6KA2RPS6KA3SRD5A2SRD5A1 | |
| SCHEMBL3080179 | 0.71 | RPS6KA2 (0.54) | RPS6KA2RPS6KA3 | |
| SCHEMBL270972 | 0.70 | POLB (0.40) | RPS6KA2RPS6KA3HSD17B10SRD5A2POLB | |
| SCHEMBL3095903 | 0.70 | RPS6KA2 (0.43) | RPS6KA2RPS6KA3 | |
| SCHEMBL50870 | 0.69 | POLB (0.39) | RPS6KA2RPS6KA3HSD17B10SRD5A2POLB | |
| SCHEMBL4144644 | 0.69 | RPS6KA2 (0.47) | RPS6KA2RPS6KA3 | |
| SCHEMBL4139802 | 0.69 | FGFR1 (0.38) | RPS6KA2RPS6KA3HSD17B10SRD5A2POLB | |
| SCHEMBL3092044 | 0.67 | RPS6KA2 (0.43) | RPS6KA2RPS6KA3SRD5A2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2518073-B1 | Compounds for the treatment of Hepatitis C | BRISTOL MYERS SQUIBB CO (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2118109-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-20140186299-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140045816-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130171098-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-07-04 | — | — | US | disclosed |
| EP-2401280-B1 | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-05-01 | — | — | EP | disclosed |
| EP-2118108-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-2518073-A1 | Compounds for the treatment of Hepatitis C | Bristol-Myers Squibb Company (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2209784-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20120115847-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-10 | — | — | US | disclosed |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226593-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
| US-20070287694-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
| US-20070275930-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-29 | — | — | US | disclosed |
| US-20070270406-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20070270405-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-22 | — | — | US | disclosed |
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270405-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | RPS6KA2 2459/4885RPS6KA3 1970/4885HSD17B10 259/4885 |
| US-20140045816-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | RPS6KA2 2459/4885RPS6KA3 1970/4885HSD17B10 259/4885 |
| US-20070184024-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | ZC3HAV1, CYP3A5, SLC10A1 | RPS6KA2 3360/4885RPS6KA3 2754/4885HSD17B10 293/4885 |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | RPS6KA2 1996/4885RPS6KA3 1278/4885HSD17B10 215/4885 |
| US-20070275930-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | RPS6KA2 2459/4885RPS6KA3 1970/4885HSD17B10 259/4885 |
| US-20070270406-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | RPS6KA2 2459/4885RPS6KA3 1970/4885HSD17B10 259/4885 |
| US-20120115847-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | RPS6KA2 1996/4885RPS6KA3 1278/4885HSD17B10 215/4885 |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, NR1H4 | RPS6KA2 2540/4885RPS6KA3 1717/4885HSD17B10 204/4885 |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | ZC3HAV1, ODC1, MED1 | RPS6KA2 1949/4885RPS6KA3 1476/4885HSD17B10 1522/4885 |
| US-20080226593-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | RPS6KA2 1996/4885RPS6KA3 1278/4885HSD17B10 215/4885 |
| US-20140186299-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | RPS6KA2 2459/4885RPS6KA3 1970/4885HSD17B10 259/4885 |
| US-20130171098-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | RPS6KA2 2459/4885RPS6KA3 1970/4885HSD17B10 259/4885 |
| US-20070287694-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, CCR5 | RPS6KA2 3470/4885RPS6KA3 2615/4885HSD17B10 566/4885 |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | RPS6KA2 1996/4885RPS6KA3 1278/4885HSD17B10 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.